Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

US Patent Granted for Verona Pharma’s RPL554

Published: Tuesday, January 01, 2013
Last Updated: Tuesday, January 01, 2013
Bookmark and Share
Company is currently carrying out clinical trials of the drug, RPL554.

Verona Pharma plc has announced that the United States Patent and Trademark Office has granted a new patent for the Company’s lead drug candidate, RPL554.

The patent is the fourth patent issued for RPL554 and related compounds in the US.

RPL554, Verona Pharma's lead drug candidate, is a dual phosphodiesterase 3 and 4 inhibitor with both bronchodilator and anti-inflammatory properties.

RPL554 is being developed for the treatment of patients with chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma.

The Company is currently carrying out clinical trials of the drug to further characterize its bronchodilator and anti-inflammatory effects.

Dr Jan-Anders Karlsson, CEO of Verona Pharma, said: “We are growing the intellectual property portfolio around the RPL554 programme and the issue of this new US Patent strengthens and harmonizes our international patent estate around RPL554 and provides exclusivity in one of the world’s leading pharmaceutical markets. We continue to develop our intellectual property rights as this is a key part of Verona Pharma’s strategy.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Verona Pharma Reports Bronchodilator Data with RPL554 in COPD Patients
Data was presented at the 2012 European Respiratory Society Annual Congress in Vienna.
Tuesday, January 15, 2013
Verona Pharma Appoints New CEO
Appointment of experienced biotechnology CEO as part of succession planning.
Friday, May 04, 2012
Verona Pharma Appoints Manchester Clinical Research Facility to Carry Out Clinical Trial with RPL554
Enrollment of patients to start Q2, with results expected early Q4 2012.
Friday, March 09, 2012
Verona Pharma Successfully Completes £3.25 Million Placing
Placing to provide Company with sufficient working capital to finance RPL554 clinical trial programme.
Monday, December 12, 2011
Verona Pharma Announces Positive Results for RPL554 in Mild Asthma at Higher Doses
Verona has completed a successful trial in which 20 mild asthmatic subjects treated with either single doses of RPL554 or placebo administered via a nebulizer.
Wednesday, February 23, 2011
Verona Pharma Applies for Approval to Test RPL554 in UK Clinical Trials
RPL554 is Verona Pharma’s lead drug compound which is a long acting bronchodilator/anti-inflammatory drug belonging to a class of drugs known as a mixed PDE 3/4 inhibitor.
Monday, February 14, 2011
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
New NIH-EPA Research Centers to Study Environmental Health Disparities
Scientists will partner with community organizations to study these concerns and develop culturally appropriate ways to reduce exposure to harmful environmental conditions.
Structure of Essential Digestive Enzyme Uncovered
Using a powerful combination of techniques from biophysics to mathematics, researchers have revealed new insights into the mechanism of a liver enzyme that is critical for human health.
Air Pollution Linked to Heart Disease
10-year project revealed air pollutants accelerate plaque build-up in arteries to the heart.
Getting a Better Look at How HIV Infects and Takes Over its Host Cells
A new approach, developed by a team of researchers led by The Rockefeller University and The Aaron Diamond AIDS Research Center (ADARC), offers an unprecedented view of how a virus infects and appropriates a host cell, step by step.
Following Tricky Triclosan
Antibacterial product flows through streams, crops.
Vitamin A May Help Improve Pancreatic Cancer Chemotherapy
The addition of high doses of a form of vitamin A could help make chemotherapy more successful in treating pancreatic cancer, according to an early study by Queen Mary University of London (QMUL).
Poverty Marks a Gene, Predicting Depression
New study of high-risk teens reveals a biological pathway for depression.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
A Boost for Regenerative Medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!